Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for rapid detection of the lung cancer biomarker USE1
Researchers combined AI-guided design with nanobiotechnology to create an affordable blood test that detects lung cancer with high accuracy, potentially accessible to more patients.
An AlphaFold3-guided aptamer biosensing platform detects the lung cancer biomarker USE1 with AUC=0.961 using quantum dot-DNA nanostructures in 30 paired tumor/normal tissue samples. The antibody-free, rapid workflow integrates AI structural modeling with nanobiotechnology for affordable cancer biomarker detection.
What the study was
- Study design
- Validation study (paired tissue samples, 30 patients)
- Population
- 30 paired lung tumor/normal tissue samples (Asan Medical Center)
- Sample size
- 30
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Journal of Nanobiotechnology
Why it surfaced
Novel integration of AI structural modeling (AlphaFold3) with aptamer SELEX and QD nanostructures achieves high diagnostic accuracy for USE1 lung cancer biomarker; antibody-free low-cost platform is clinically attractive. Limited by small n=30 single-center validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.